WO2006109195A3 - Modulation de reponse immunitaire par hemaglutinine filamenteuse - Google Patents
Modulation de reponse immunitaire par hemaglutinine filamenteuse Download PDFInfo
- Publication number
- WO2006109195A3 WO2006109195A3 PCT/IB2006/001563 IB2006001563W WO2006109195A3 WO 2006109195 A3 WO2006109195 A3 WO 2006109195A3 IB 2006001563 W IB2006001563 W IB 2006001563W WO 2006109195 A3 WO2006109195 A3 WO 2006109195A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- immune response
- modulation
- filamentous haemagglutinin
- fha
- suppression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55544—Bacterial toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Procédé de modulation de réponse immunitaire par administration d'hémaglutinine filamenteuse ou bien de dérivé, mutant, fragment, variant ou peptide correspondant. Il est apparu que l'IL-17 était un médiateur pro-inflammatoire important entraînant une pathologie sous forme de maladie auto-immune. On a démontré que l'hémaglutinine filamenteuse supprimait la production d'IL-23 et d'IL-27. La suppression de ces cytokines supprime à son tour l'expansion clonale des lymphocytes T produisant de l'IL-17. La suppression des lymphocytes en question induit ensuite un abaissement de la production de cytokine IL-17.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0507561.9 | 2005-04-14 | ||
| GBGB0507561.9A GB0507561D0 (en) | 2005-04-14 | 2005-04-14 | Modulation of an immune response by filamentous haemagglutinin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2006109195A2 WO2006109195A2 (fr) | 2006-10-19 |
| WO2006109195A3 true WO2006109195A3 (fr) | 2007-04-05 |
Family
ID=34611130
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IB2006/001563 Ceased WO2006109195A2 (fr) | 2005-04-14 | 2006-04-18 | Modulation de reponse immunitaire par hemaglutinine filamenteuse |
Country Status (2)
| Country | Link |
|---|---|
| GB (1) | GB0507561D0 (fr) |
| WO (1) | WO2006109195A2 (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI426918B (zh) | 2007-02-12 | 2014-02-21 | Merck Sharp & Dohme | Il-23拮抗劑於治療感染之用途 |
| WO2014037952A1 (fr) * | 2012-09-10 | 2014-03-13 | Yeda Research And Development Co. Ltd At The Weizmann Institute Of Science | Thérapie d'immunomodulation individualisée pour des troubles neurodégénératifs, une lésion du snc et la démence liée à l'âge |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005034983A1 (fr) * | 2003-10-14 | 2005-04-21 | The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin | Utilisation d'hemagglutinine filamenteuse dans le traitement et/ou la prevention de troubles d'origine immunologique |
-
2005
- 2005-04-14 GB GBGB0507561.9A patent/GB0507561D0/en not_active Ceased
-
2006
- 2006-04-18 WO PCT/IB2006/001563 patent/WO2006109195A2/fr not_active Ceased
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005034983A1 (fr) * | 2003-10-14 | 2005-04-21 | The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin | Utilisation d'hemagglutinine filamenteuse dans le traitement et/ou la prevention de troubles d'origine immunologique |
Non-Patent Citations (2)
| Title |
|---|
| DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; April 2004 (2004-04-01), BRAAT HENRI ET AL: "Immuno-modulating effect of filamentous hemagglutinine A of Bordetella pertussis in experimental colitis", XP002413239, Database accession no. PREV200600084431 * |
| GASTROENTEROLOGY, vol. 126, no. 4, Suppl. 2, April 2004 (2004-04-01), DIGESTIVE DISEASE WEEK/105TH ANNUAL MEETING OF THE AMERICAN-GASTROENTEROLOGICAL-ASSOCIATION; NEW ORLEANS, LA, USA; MAY 16 20, 2004, pages A284 - A285, ISSN: 0016-5085 * |
Also Published As
| Publication number | Publication date |
|---|---|
| GB0507561D0 (en) | 2005-05-18 |
| WO2006109195A2 (fr) | 2006-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IS2859B (is) | Hámörkuð tjáning á HPV 31 L1 í gersveppi | |
| NZ701614A (en) | Endophytes and related methods (4) | |
| EP1687329B8 (fr) | Expression optimisee de hpv 58 l1 dans de la levure | |
| AU2003244855A1 (en) | Method to enhance an immune response of nucleic acid vaccination | |
| EA200801735A1 (ru) | Антиамилоидные иммуногенные композиции, способы и применения | |
| MY140664A (en) | Optimized expression of hpv 45 l1 in yeast | |
| MX369784B (es) | Metodo de modificacion del punto isoelectrico de anticuerpos mediante la sustitucion de aminoacidos en region de determinacion de complementariedad (cdr). | |
| WO2005089164A3 (fr) | Induction de reponses immunitaires cellulaires au papillomavirus humain utilisant des compositions peptidiques et d'acides nucleiques | |
| WO2008033966A3 (fr) | Particules de réplicon d'alphavirus correspondant à des antigènes de protéines utilisées en qualité d'adjuvants immunologiques | |
| AR078468A1 (es) | Levadura y metodo para producir etanol | |
| WO2009004842A1 (fr) | Vaccin pour maladie de l'œdème porcine | |
| UA102097C2 (ru) | Способ лечения воспалительного заболевания с применением соединения, которое нейтрализует gm-csf, и соединения, которое нейтрализует il-17 | |
| WO2005120558A3 (fr) | Procede pour la fabrication de compositions comportant des proteines de choc thermique ou de l'alpha-2-macroglobuline pour le traitement du cancer et de maladie infectieuse | |
| WO2007099348A3 (fr) | Peptide et ses utilisations | |
| EP2542574A4 (fr) | Procédé pour la production de la protéine interféron recombinante soluble sans dénaturation | |
| WO2006109195A3 (fr) | Modulation de reponse immunitaire par hemaglutinine filamenteuse | |
| SI1530628T1 (sl) | Postopek za proizvodnjo s temperaturo induciranih lizatov tumorskih celic za uporabo kot imunogenske spojine | |
| WO2005121328A8 (fr) | Methode permettant d'ameliorer un etat inflammatoire de la peau | |
| WO2004053092A3 (fr) | Polypeptides pellino humains | |
| ATE494377T1 (de) | Vakzine gegen ipnv die aus hefezellen isoliert werden | |
| ATE474596T1 (de) | Impfstoff gegen humanes papillomavirus zur oralen verabreichung | |
| WO2010111586A3 (fr) | Immunisation par voie muqueuse | |
| WO2005123112A3 (fr) | Procede permettant de renforcer la reponse immunitaire a un vaccin | |
| WO2006002195A3 (fr) | Procede de complexation d'une proteine au moyen d'un systeme disperse et proteines ainsi obtenues | |
| WO2009027478A3 (fr) | Procédé d'élimination de conservateurs à partir d'une préparation pharmaceutique liquide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
| NENP | Non-entry into the national phase |
Ref country code: RU |
|
| WWW | Wipo information: withdrawn in national office |
Country of ref document: RU |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 06765511 Country of ref document: EP Kind code of ref document: A2 |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 06765511 Country of ref document: EP Kind code of ref document: A2 |